Amrinone - CAS 60719-84-8
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Phosphodiesterase (PDE)
Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It has the ability to stimulate calcium ion influx into the cardiac cell. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator. It acts by inhibiting the breakdown of both cAMP and cGMP by the phosphodiesterase (PDE3) enzyme. It is a drug that may improve the prognosis in patients with congestive heart failure. It has been shown to increase the contractions initiated in the heart by high gain calcium induced calcium release (CICR). It was developed by Sanofi and has been listed.
Publictions citing BOC Sciences Products
  • >> More
Pale Beige to Yellow Solid
DMSO (Slightly), Methanol (Slightly)
Amrinone is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator.
Quality Standard:
CP standard
Kilograms to Tons
Boiling Point:
451.5±45.0 °C | Condition: Press: 760 Torr
Melting Point:
295 °C (decomp)
1.277±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Amrinone was developed by Sanofi and has been listed.
1.A Systematic Review of Topical Vasodilators for the Treatment of Intraoperative Vasospasm in Reconstructive Microsurgery.
Vargas CR1, Iorio ML, Lee BT. Plast Reconstr Surg. 2015 Aug;136(2):411-22. doi: 10.1097/PRS.0000000000001431.
BACKGROUND: Intraoperative vasospasm during reconstructive microsurgery is common, often unpredictable, and potentially devastating with regard to flap survival. Current methods of pharmacologic management vary, and may be shifting as a result of changes in the availability of individual medications. This review aims to provide a concise examination of the published literature regarding use, efficacy, and adverse effects of the agents described for local management of vascular spasm during microsurgery.
2.ANP and CNP activate CFTR expressed in Xenopus laevis oocytes by direct activation of PKA.
Stahl K1,2, Stahl M1,2, de Jonge HR2,3, Forrest JN Jr1,2. J Recept Signal Transduct Res. 2015;35(5):493-504. doi: 10.3109/10799893.2015.1015738. Epub 2015 May 27.
CONTEXT: Acting through different receptors, natriuretic peptides (atrial natriuretic peptide [ANP], brain type natriuretic peptide [BNP] and C-type natriuretic peptide [CNP]) increase intracellular cGMP, which then stimulates different pathways that activate fluid secretion.
3.The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.
Guth BD1, Chiang AY2, Doyle J3, Engwall MJ4, Guillon JM5, Hoffmann P6, Koerner J7, Mittelstadt S8, Ottinger S9, Pierson JB10, Pugsley MK11, Rossman EI12, Walisser J13, Sarazan RD3. J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:70-90. doi: 10.1016/j.vascn.2015.02.002. Epub 2015 Apr 3.
INTRODUCTION: Drug-induced effects on the cardiovascular system remain a major cause of drug attrition. While hemodynamic (blood pressure (BP) and heart rate (HR)) and electrophysiological methods have been used in testing drug safety for years, animal models for assessing myocardial contractility are used less frequently and their translation to humans has not been established. The goal of these studies was to determine whether assessment of contractility and hemodynamics, when measured across different laboratories using the same protocol, could consistently detect drug-induced changes in the inotropic state of the heart using drugs known to have clinically relevant positive and negative effects on myocardial contractility.
4.Alcohols as alkylating agents in heteroarene C-H functionalization.
Jin J1, MacMillan DW1. Nature. 2015 Sep 3;525(7567):87-90. doi: 10.1038/nature14885. Epub 2015 Aug 26.
Redox processes and radical intermediates are found in many biochemical processes, including deoxyribonucleotide synthesis and oxidative DNA damage. One of the core principles underlying DNA biosynthesis is the radical-mediated elimination of H2O to deoxygenate ribonucleotides, an example of 'spin-centre shift', during which an alcohol C-O bond is cleaved, resulting in a carbon-centred radical intermediate. Although spin-centre shift is a well-understood biochemical process, it is underused by the synthetic organic chemistry community. We wondered whether it would be possible to take advantage of this naturally occurring process to accomplish mild, non-traditional alkylation reactions using alcohols as radical precursors. Because conventional radical-based alkylation methods require the use of stoichiometric oxidants, increased temperatures or peroxides, a mild protocol using simple and abundant alkylating agents would have considerable use in the synthesis of diversely functionalized pharmacophores.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products

CAS 1904611-63-7 PDE1-IN-2

(CAS: 1904611-63-7)

PDE1-IN-2 is an inhibitor of PDE1 that has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.

CAS 1160521-50-5 PDE1-IN-1

(CAS: 1160521-50-5)

PDE1-IN-1 is a potent PDE1 inhibitor and neuroprotective agent.

CAS 947620-48-6 RVT-501

(CAS: 947620-48-6)

RVT-501, also referred to E6005, is a selective phosphodiesterase 4 (PDE4) inhibitor (IC50= 2.8 nM) with potential effect to treat atopic dermatitis.

CAS 60719-84-8 Amrinone

(CAS: 60719-84-8)

Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic ag...

CAS 171599-83-0 Sildenafil Citrate

Sildenafil Citrate
(CAS: 171599-83-0)

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...

CAS 1238697-26-1 TAK-063

(CAS: 1238697-26-1)

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...

BRL 50481
(CAS: 433695-36-4)

BRL 50481 is a potent, selective substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM).

(CAS: 1239278-59-1)

This active molecular is a Type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor originated by Chiesi Farmaceutici with IC50 value of 0.026 ± 0.006 nM. CH...

CAS 139755-83-2 Sildenafil

(CAS: 139755-83-2)

An orally active selective type 5 cGMP phosphodiesterase inhibitor.

CAS 81840-15-5 Vesnarinone

(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

CAS 106730-54-5 Olprinone

(CAS: 106730-54-5)

Olprinone(Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.

(CAS: 799841-02-4)

FR-229934 is a Type 5 cyclic nucleotide phosphodiesterase inhibitor. In Feb 2008, preclinical for Erectile dysfunction in Japan was discontinued.

CAS 1440898-61-2 Deltarasin

(CAS: 1440898-61-2)

Deltarasin inhibits the interaction of RAS with PDEδ with KD of 41 nM. Inhibition of PDEδ-KRAS interaction by Deltarasin suppresses proliferation of human pancr...

CAS 152633-54-0 Win-62005

(CAS: 152633-54-0)

Win-62005 competitively and selectively inhibits cyclic GMP-inhibitable low Km cyclic AMP phosphodiesterase (PDE III) from rat heart and canine aorta (Kis= 25 a...

CAS 85416-75-7 (R)-(-)-Rolipram

(CAS: 85416-75-7)

(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor. It is 2.5-fold more potent than (+)-rolipram in inhibiting membrane-bound PDE 4.

CAS 6493-05-6 Pentoxifylline

(CAS: 6493-05-6)

Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...

CAS 119615-63-3 Olprinone Hydrochloride

Olprinone Hydrochloride
(CAS: 119615-63-3)

Olprinone is a selective phosphodiesterase 3 (PDE3) inhibitor. Olprinone is used as cardiotonic agent with positive inotropic and vasodilating effects. Olprinon...

CAS 862189-96-6 Mirodenafil dihydrochloride

Mirodenafil dihydrochloride
(CAS: 862189-96-6)

Mirodenafil dihydrochloride is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.

CAS 1144035-53-9 PF-8380

(CAS: 1144035-53-9)

PF-8380 blocks inflammation-induced LPA synthesis. PF-8380 works both in vitro and in vivo through direct inhibition of autotaxin. In human whole blood PF-8380 ...

(CAS: 245329-99-1)

CI-1018 is a selective type 4 phosphodiesterase inhibitor associated with vasculitis. CI-1018 has been in development to suppress inflammation.

Chemical Structure

CAS 60719-84-8 Amrinone

Quick Inquiry

Verification code

Featured Items